Search

Your search keyword '"A. Calmy"' showing total 2,890 results

Search Constraints

Start Over You searched for: Author "A. Calmy" Remove constraint Author: "A. Calmy"
2,890 results on '"A. Calmy"'

Search Results

1. Viral suppression and retention in HIV care during the postpartum period among women living with HIV: a longitudinal multicenter cohort studyResearch in context

2. Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells

3. Evaluation of the Xpert MTB/RIF assay for the diagnosis of smear-negative pulmonary and extrapulmonary tuberculosis in Madagascar

4. Infectious disease events in people with HIV receiving kidney transplantation: Analysis of the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study

5. Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR’HIV): a multicenter, international, non-randomized clinical trial study protocol

6. Unusual staphylococcal toxic shock syndrome presenting as a scarlet-like fever

7. Dolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. A case report and review

8. SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa

9. Booster-free anti-retroviral therapy for persons living with HIV and multidrug resistance (B-Free): protocol for a multicentre, multistage, randomised, controlled, non-inferiority trial

10. Patient and public involvement in HIV research: a mapping review and development of an online evidence map

11. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland

12. Transcriptional profile of Mycobacterium tuberculosis infection in people living with HIV

15. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial

16. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

19. Viral suppression and retention in HIV care during the postpartum period among women living with HIV: a longitudinal multicenter cohort study

20. Revealing viral and cellular dynamics of HIV-1 at the single-cell level during early treatment periods

21. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection

22. Mpox in people with advanced HIV infection: a global case series

23. Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial

24. Capacity Building in Sub-Saharan Africa as Part of the INTENSE-TBM Project During the COVID-19 Pandemic

26. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study

27. Dexamethasone exposure in normal‐weight and obese hospitalized COVID‐19 patients: An observational exploratory trial

28. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon

30. How the COVID-19 Pandemic Alters the Landscapes of the HIV and Tuberculosis Epidemics in South Africa: A Case Study and Future Directions

31. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses

32. Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID‐19: The Swiss COVID‐HEP randomized clinical trial

33. Population pharmacokinetics of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIV.

34. Patient and public involvement in HIV research: a mapping review and development of an online evidence map.

35. Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy.

37. Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial

38. Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study

40. Responses to controlled release potassium fertilisers in agriculture following phosphate mining

41. Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial

44. Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV

45. Costs and acceptability of simplified monitoring in HIV-suppressed patients switching to dual therapy: the SIMPL’HIV open-label, factorial randomised controlled trial

46. Time Trends in Causes of Death in People With Human Immunodeficiency Virus: Insights From the Swiss HIV Cohort Study

47. Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR’HIV): a multicenter, international, non-randomized clinical trial study protocol

48. Deciphering factors linked with reduced SARS-CoV-2 susceptibility in the Swiss HIV Cohort Study

49. Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy

50. Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy

Catalog

Books, media, physical & digital resources